Our researchers are working on a number of development projects on selected growth disorders and metabolic diseases in the therapeutic area of Endocrinology. The Merck Serono division can build on its long-standing experience in these therapeutic indications.
Our U.S. subsidiary EMD Serono acquired the commercialization rights to tesamorelin, a growth hormone-releasing factor analogue with therapeutic potential in a variety of anabolic and lipolytic indications. The compound is in the final stages of its second Phase III clinical trial to assess the safety and efficacy when used to reduce excess abdominal fat in HIV patients with lipodystrophy. The development of a high-dose recombinant human growth hormone for the treatment of HIV-associated adipose redistribution syndrome (HARS) was discontinued and an impairment loss was recognized for the intangible assets capitalized to date.
In cooperation with the U.S. biopharmaceutical company Ambrx, we are studying the long-acting growth hormone ARX-201 for the treatment of growth hormone deficiency.
In other projects we are working on the constant further development of our application devices.
back
